Treatment with anti-IL-6 or anti-IL-6 receptor antibodies reduces PD-L1 expression patient-derived xenografts, which indicates that tumor-induced peripheral immunosuppression promotes brain metastases [19]. Here, IL6 is linked to neoplasm.